Cargando…

CTLA-4 +49A/G and CT60 gene polymorphisms in primary Sjögren syndrome

CTLA-4 encodes cytotoxic T lymphocyte-associated antigen-4, a cell-surface molecule providing a negative signal for T-cell activation. CTLA-4 gene polymorphisms have been widely studied in connection with genetic susceptibility to various autoimmune diseases, but studies have led to contradictory re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gottenberg, Jacques-Eric, Loiseau, Pascale, Azarian, Mariam, Chen, Chun, Cagnard, Nicolas, Hachulla, Eric, Puechal, Xavier, Sibilia, Jean, Charron, Dominique, Mariette, Xavier, Miceli-Richard, Corinne
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1906800/ https://www.ncbi.nlm.nih.gov/pubmed/17341301 http://dx.doi.org/10.1186/ar2136

Ejemplares similares

CTLA-4 polymorphism and primary Sjögren's syndrome: authors' response
por: Miceli-Richard, Corinne, et al.
Publicado: (2007)

No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndrome
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2006)

Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren’s Syndrome. Data at Enrollment in the Prospective ASSESS Cohort
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2013)

B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome
por: Ittah, Marc, et al.
Publicado: (2006)

Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren’s Syndrome?
por: Devauchelle-Pensec, Valérie, et al.
Publicado: (2015)

Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity
por: Sellam, Jérémie, et al.
Publicado: (2009)

Seasonal effect on fatigue, pain and dryness in primary Sjögren’s syndrome
por: Duret, Pierre-Marie, et al.
Publicado: (2020)

Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort
por: Carvajal Alegria, Guillermo, et al.
Publicado: (2016)

Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2009)

Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren’s syndrome in the JOQUER randomized trial
por: Bodewes, Iris L A, et al.
Publicado: (2020)

Revisiting the JOQUER trial: stratification of primary Sjögren’s syndrome and the clinical and interferon response to hydroxychloroquine
por: Collins, Alexis, et al.
Publicado: (2021)

Sjögren’s syndrome: state of the art on clinical practice guidelines
por: Romão, Vasco C, et al.
Publicado: (2018)

EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide
por: Seror, Raphaèle, et al.
Publicado: (2015)

Discrepancy of Serological and Molecular Patterns of Circulating Epstein-Barr Virus Reactivation in Primary Sjögren's Syndrome
por: Sanosyan, Armen, et al.
Publicado: (2019)

Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome
por: Seror, Raphaele, et al.
Publicado: (2022)

CTLA4 polymorphism and primary Sjögren's syndrome
por: Lester, Susan, et al.
Publicado: (2007)

Impact of patient ancestry on heterogeneity of Sjögren’s disease
por: Beydon, Maxime, et al.
Publicado: (2023)

Cognitive Dysfunction and Dementia in Primary Sjögren's Syndrome
por: Blanc, Frederic, et al.
Publicado: (2013)

Inclusion body myositis and Sjögren’s syndrome: the association works both ways
por: Giannini, Margherita, et al.
Publicado: (2022)

ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome?
por: Payet, J, et al.
Publicado: (2015)

Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis
por: Rivière, Elodie, et al.
Publicado: (2018)

Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR Cohort
por: Seror, Raphaèle, et al.
Publicado: (2016)

Variability of Primary Sjögren's Syndrome Is Driven by Interferon‐α and Interferon‐α Blood Levels Are Associated With the Class II HLA–DQ Locus
por: Trutschel, Diana, et al.
Publicado: (2022)

Chronic stimulation with SARS-CoV-2 spike protein does not trigger autoimmunity
por: Scherlinger, Marc, et al.
Publicado: (2023)

Characteristics of Sjögren’s syndrome associated with rheumatoid arthritis
por: Hassold, Nolan, et al.
Publicado: (2022)

Overlap between differentially methylated DNA regions in blood B lymphocytes and genetic at-risk loci in primary Sjögren's syndrome
por: Miceli-Richard, Corinne, et al.
Publicado: (2016)

Efficacy of daratumumab in refractory primary Sjögren disease
por: Nocturne, Gaetane, et al.
Publicado: (2023)

Innate immunity triggers IL-32 expression by fibroblast-like synoviocytes in rheumatoid arthritis
por: Alsaleh, Ghada, et al.
Publicado: (2010)

B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis
por: François, Antoine, et al.
Publicado: (2013)

Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome
por: Brito-Zerón, Pilar, et al.
Publicado: (2019)

Association between the CTLA4 +49A/G (rs231775) and CT60 (rs3087243) gene variants with vitiligo: study on a Mexican population()
por: Salinas-Santander, Mauricio Andrés, et al.
Publicado: (2022)

miR-346 Controls Release of TNF-α Protein and Stability of Its mRNA in Rheumatoid Arthritis via Tristetraprolin Stabilization
por: Semaan, Noha, et al.
Publicado: (2011)

CTLA-4 (+49A/G) Polymorphism and Type-1 Diabetes in Turkish Children
por: Çelmeli, Fatih, et al.
Publicado: (2013)

CTLA4 +49AG (rs231775) and CT60 (rs3087243) gene variants are not associated with alopecia areata in a Mexican population from Monterrey Mexico()()
por: Salinas-Santander, Mauricio Andrés, et al.
Publicado: (2020)

The Role of CTLA-4 Exon-1 49 A/G Polymorphism and Soluble CTLA-4 Protein Level in Egyptian Patients with Behçet's Disease
por: Abdel Galil, Sahar M., et al.
Publicado: (2014)

Alteration of innate lymphoid cell homeostasis mainly concerns salivary glands in primary Sjögren’s syndrome
por: Kawka, Lou, et al.
Publicado: (2023)

Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2019)

Low Influenza, Pneumococcal and Diphtheria–Tetanus–Poliomyelitis Vaccine Coverage in Patients with Primary Sjögren’s Syndrome: A Cross-Sectional Study
por: Jacques, Morel, et al.
Publicado: (2019)

Efficacy of Epratuzumab, an Anti‐CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials
por: Gottenberg, Jacques‐Eric, et al.
Publicado: (2018)

CTLA-4 A49G GENE POLYMORPHISM IS NOT ASSOCIATED WITH VITILIGO IN SOUTH INDIAN POPULATION
por: Deeba, Farha, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_1sk2o0t06epia81muhoin9iu22